J7665 HCPCS Level II code: Mannitol, administered through an inhaler, 5 mg
J7665 is the HCPCS code for “Mannitol, administered through an inhaler, 5 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7665Mannitol, administered through an inhaler, 5 mg
Short description: Mannitol for inhaler
HCPCS · United States
Medicare details
The indicators CMS publishes with J7665 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Jan 1, 2012
Where J7665 sits
- 1J codesDrugs administered other than orally
- 2Active code J7665Mannitol, administered through an inhaler, 5 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7665 mean?
J7665 is the HCPCS code for “Mannitol, administered through an inhaler, 5 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7665?
CMS lists J7665’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7665
All J codesJ7649Isoetharine hcl, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligramJ7650Isoetharine hcl, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7657Isoproterenol hcl, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7658Isoproterenol hcl, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per milligramJ7659Isoproterenol hcl, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligramJ7660Isoproterenol hcl, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7667Metaproterenol sulfate, inhalation solution, compounded product, concentrated form, per 10 milligramsJ7668Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 10 milligramsJ7669Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligramsJ7670Metaproterenol sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per 10 milligramsJ7674Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mgJ7676Pentamidine isethionate, inhalation solution, compounded product, administered through dme, unit dose form, per 300 mg